An Open-label Phase 1 Trial to Determine the Pharmacokinetics, Pharmacodynamics and Safety of GH001 Administered Via a GH001 Aerosol Delivery System in Healthy Subjects
The primary objectives of this trial are to determine the pharmacokinetic (PK) profile and the safety and tolerability of GH001 delivered via a proprietary aerosol delivery device in healthy subjects after single-dose administration.
- Status
- planned
- Phase
- Phase 1
- Institution
- GH Research Ireland Limited
- Start date
- 2026-04-01
- End date
- 2026-05-01
- Registry ID
- NCT07540494
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.